查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863412

按產品分類、治療領域、通路、給藥途徑和最終用戶分類的中軸型脊椎關節炎市場－2025-2032年全球預測

Axial Spondyloarthritis Market by Product Class, Treatment Line, Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，中軸型脊椎關節炎市場將成長至 103.2 億美元，複合年成長率為 7.73%。

主要市場統計數據
基準年 2024 56.8億美元
預計年份：2025年 61.2億美元
預測年份：2032年 103.2億美元
複合年成長率 (%) 7.73%

中軸型脊椎關節炎的全面概述：重點介紹臨床複雜性、診斷障礙、治療模式以及影響相關人員決策的不斷變化的優先事項

中軸型脊椎關節炎（ASA）是一種複雜的慢性發炎性疾病，主要涉及脊椎和骶髂關節，導致許多患者出現疼痛、僵硬和長期功能障礙。臨床醫師面臨許多診斷挑戰，包括症狀的異質性、與機械性腰痛的重疊，以及需要將臨床評估與影像生物標記資訊結合。免疫學和分子醫學的進步正在改變人們對該疾病的臨床認知，但在早期檢測、治療順序和長期管理策略方面仍然存在挑戰。

變革性的臨床、醫療服務和價值驅動型進展正在匯聚，重新定義中軸型脊椎關節炎在整個醫療路徑中的診斷、治療和管理方式。

中軸型脊椎關節炎的治療格局正在經歷變革時期，這主要得益於標靶治療的突破、不斷更新的安全性數據以及患者期望的改變。白細胞介素-17抑制劑和Janus激酶抑制劑的出現，拓展了腫瘤壞死因子抑制劑以外的治療選擇，迫使臨床醫生重新思考治療順序和個人化策略。同時，不斷累積的真實世界數據和註冊登記數據揭示了不同患者亞群之間的治療反應差異，因此需要開發更精細的治療流程，並將重點放在長期疾病控制而非暫時緩解症狀上。

為應對關稅和全球貿易中斷帶來的成本壓力，以及由此對治療取得造成的影響，供應鏈韌性、臨床營運和合約策略正在接受審查。

貿易政策的轉變，包括2025年生效的關稅調整，正為用於治療中軸型脊椎關節炎的生技藥品和小分子藥物的全球供應鏈帶來新的複雜性。由於原料藥和成品進口關稅的提高，導致到岸成本上升，並對現有定價協議構成壓力，製藥企業和經銷商被迫重新評估籌資策略。儘管一些公司歷來採用分散式製造地模式，但關稅的實施正在加速關於近岸外包、雙重採購和策略性庫存佈局的討論，以確保治療的連續性並最大限度地減少對關鍵患者群體的影響。

按產品分類、治療領域、分銷管道、給藥途徑和最終用戶進行細分分析，可以揭示可用於臨床和商業策略的可操作差異化因素。

詳細的市場細分分析揭示了不同產品類別、治療方案、分銷管道、給藥途徑和終端用戶環境之間的顯著動態，這些差異對臨床和商業性選擇產生重大影響。在產品類別中，傳統的緩解疾病抗風濕藥物（DMARDs），包括羥氯喹、胺基甲基葉酸和柳氮磺胺吡啶等藥物，被定位為特定患者群體的基礎治療方法，尤其適用於臨床醫生旨在控制合併症或限制生技藥品製劑暴露的情況。以Brodalumab 、ixekizumab和sectinimab為代表的IL-17抑制劑，在軸性發炎生物標記和臨床表現型提示高反應可能性的Janus，已建立起獨特的利基市場。 Janus激酶抑制劑，包括filgotinib、tofacitinib和Upadacitinib ，是口服標靶治療，適用於尋求便利性和快速症狀控制的患者。

區域間在監管、支付模式和醫療基礎設施方面的差異，造成了不同的醫療服務取得管道，需要客製化的證據和分銷策略。

區域趨勢反映了流行病學、法規環境、支付方框架和醫療服務基礎設施的差異，這些差異影響著醫療服務的可近性和策略。在美洲，醫療系統採用公私支付機制相結合的方式，並強調基本契約和專科藥房網路，從而促進患者獲得先進的生技藥品和口服標靶藥物。該地區擴大利用真實世界數據（RWD）舉措和患者登記系統來支持價值提案和報銷談判，同時遠端醫療的擴展也加強了遠端監測和依從性干預。

競爭優勢依賴差異化的證據、整合的患者權益倡導、可靠的供應以及貫穿整個治療生命週期的策略夥伴關係。

中軸型脊椎關節炎領域的競爭格局由成熟的生技藥品製劑產品線、新興的標靶分子藥物以及提供輸注、配送和患者支持的專業服務供應商共同構成​​。現有的腫瘤壞死因子抑制劑產品組合繼續利用多年的臨床經驗和廣泛的安全性數據，而包括白細胞介素-17抑制劑和Janus激酶抑制劑在內的新型藥物類別則致力於在特定患者群體中展現臨床差異化優勢，並提供更便捷的給藥途徑。

為了將臨床創新轉化為永續的患者影響，應優先考慮綜合證據產生、加強供應鏈韌性、與支付方合作、定製商業化和教育。

為因應臨床複雜性、政策變化和商業性壓力，產業領導者應優先採取一系列切實有效且影響深遠的行動。首先，透過投資比較療效研究、真實世界資料收集和病患報告結局研究，使證據生成與監管機構和支付方的期望保持一致，從而明確長期獲益和安全性。其次，透過製造地多元化、策略性庫存管理和物流夥伴關係，增強供應鏈韌性，以減輕貿易政策和關稅相關干擾的影響。

我們以證據為導向的多學科調查方法，結契約行評審的科學論文、專家訪談、監管分析和營運情報，從而得出可操作的臨床和商業性見解。

本研究綜述基於多學科方法，整合了初級和二級研究、專家諮詢以及系統性證據審查，對中軸型脊椎關節炎進行了全面的觀點。疾病生物學、治療機制和安全性概況的基礎建立在臨床和科學文獻、指南文件、監管溝通以及同行評審研究的基礎上。此外，也透過對臨床醫生、專科藥劑師和市場進入負責人的專案訪談，補充了對真實世界臨床實踐模式、診斷流程以及醫保談判趨勢的了解。

整合臨床進展、營運韌性與策略夥伴關係，打造協調一致的方案，加速以病人為中心的治療效果和永續的醫療服務取得。

中軸型脊椎關節炎既帶來了持續的挑戰，也為臨床創新和策略行動提供了明確的機會。儘管診斷延遲和患者反應的差異性持續阻礙著治療進程，但包括生技藥品和標靶藥物在內的治療選擇不斷擴展，為實現持久的疾病控制和改善長期功能開闢了新的途徑。政策趨勢和貿易動態雖然增加了營運的複雜性，但也促使企業在供應鏈韌性、生產多元化和透明合約等方面進行有利可圖的投資。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 對於第一線TNF抑制劑無效的非放射性中軸型脊椎關節炎患者，JAK抑制劑的快速應用
  • 增加對生物標記驅動的診斷技術的投資，以早期發現中軸型脊椎關節炎的進展
  • 擴展遠端醫療平台，整合病患報告結果，用於遠距監測疾病活動
  • 在研產品測試中，針對TNF和IL-17通道的雙特異性抗體候選藥物湧現。
  • 來自Etanercept和Adalimumab單抗生物相似藥日益激烈的競爭正在影響定價和市場進入策略。
  • 引入定量MRI評分演算法以改善早期診斷和治療分層
  • 採用基於價值的合約模式與支付方合作，重點關注生技藥品在治療中軸型脊椎關節炎的長期功能性療效。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類別分類的中軸型脊椎關節炎市場

  • 傳統DMARDs
    • 羥氯喹
    • 胺基甲基葉酸
    • 柳氮磺胺吡啶
  • IL-17抑制劑
    • Brodalumab
    • 伊克珠單抗
    • 塞克替尼單抗
  • JAK抑制劑
    • 菲戈替尼
    • 託法替尼
    • Upadacitinib
  • 非類固醇消炎劑（NSAIDs）
    • 雙氯芬酸鈉
    • Ibuprofen
    • 萘普生
  • TNF抑制劑
    • Adalimumab
    • 賽妥珠單抗
    • Etanercept
    • 戈利木單抗
    • Infliximab

9. 中軸型脊椎關節炎市場（依治療線分類）

  • 一線治療
  • 二線治療
  • 三線治療

第10章 中軸型脊椎關節炎市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 中軸型脊椎關節炎市場（依給藥途徑分類）

  • 注射
  • 靜脈注射
  • 口服

第12章 軸性脊椎關節炎市場（依最終用戶分類）

  • 居家醫療
  • 醫院
  • 專科診所

第13章 中軸型脊椎關節炎市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 軸性脊椎關節炎市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國中軸型脊椎關節炎市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Novartis AG
    • Janssen BIoTech, Inc.
    • Eli Lilly and Company
    • UCB SA
    • Amgen Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
Product Code: MRR-5C6F41F5AF7D

The Axial Spondyloarthritis Market is projected to grow by USD 10.32 billion at a CAGR of 7.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.68 billion
Estimated Year [2025] USD 6.12 billion
Forecast Year [2032] USD 10.32 billion
CAGR (%) 7.73%

A comprehensive orientation to axial spondyloarthritis highlighting clinical complexity, diagnostic barriers, treatment paradigms, and the evolving priorities shaping stakeholder decision-making

Axial spondyloarthritis represents a complex chronic inflammatory condition that primarily affects the spine and sacroiliac joints, producing pain, stiffness, and long-term functional impairment for many patients. Clinicians face diagnostic challenges driven by heterogenous symptom presentation, overlaps with mechanical back pain, and the need to combine clinical assessment with imaging and biomarker information. Advances in immunology and molecular medicine are reshaping clinical understanding, yet gaps persist in early identification, therapeutic sequencing, and long-term management strategies.

Patients commonly navigate protracted pathways before receiving a definitive diagnosis, which influences both clinical outcomes and healthcare resource utilization. In parallel, therapeutic decision-making increasingly integrates targeted biologics and small molecules alongside conventional disease-modifying agents and symptomatic management with nonsteroidal anti-inflammatory drugs. The commercial and clinical landscape is evolving as new mechanisms of action demonstrate differential efficacy across patient phenotypes, safety profiles, and routes of administration. Stakeholders must therefore balance efficacy, tolerability, patient preference, and delivery models to optimize adherence and outcomes.

This introduction sets the stage for a detailed exploration of transformative shifts, policy influences, segmentation-driven opportunity areas, regional dynamics, competitive interplay, and actionable recommendations. The objective is to equip clinicians, payers, life sciences executives, and distribution leaders with a concise yet comprehensive orientation to the current state and near-term inflection points in axial spondyloarthritis management.

Transformative clinical, delivery, and value-based evolutions are converging to redefine how axial spondyloarthritis is diagnosed, treated, and managed across care pathways

The treatment landscape for axial spondyloarthritis has entered a period of transformative change driven by breakthroughs in targeted therapies, evolving safety evidence, and shifts in patient expectations. The emergence of interleukin-17 inhibitors and Janus kinase inhibitors has broadened therapeutic options beyond tumor necrosis factor inhibitors, prompting clinicians to rethink sequencing and personalization strategies. At the same time, growing real-world evidence and registry data have begun to delineate differential responses among patient subgroups, prompting more nuanced treatment algorithms and a stronger focus on long-term disease control rather than transient symptom relief.

Concurrently, care delivery models are adapting to patient preferences for convenience and continuity. The proliferation of oral targeted therapies and optimized infusion or injection delivery protocols has intensified competition across routes of administration, while digital health platforms are augmenting monitoring, adherence support, and remote consultations. Payer frameworks are responding to these clinical advances with increasingly outcome-oriented reimbursement models; value frameworks now place greater emphasis on sustained functional improvement, reduced flares, and avoidance of long-term disability.

Finally, innovation extends beyond pharmacology into diagnostics and biomarkers that aim to shorten diagnostic delay and enable precision prescribing. These diagnostic advances, paired with evolving clinical practice guidelines and multidisciplinary care pathways, are collectively reshaping how patients are identified, treated, and monitored, creating new windows for strategic investment and care model redesign.

Supply chain resilience, clinical operations, and contracting strategies are being reoriented in response to tariff-driven cost pressures and global trade disruptions affecting therapy access

Trade policy shifts, including tariff adjustments enacted in 2025, have injected new complexity into the global supply chains that underpin biologic and small molecule availability for axial spondyloarthritis. Pharmaceutical manufacturers and distributors have had to reassess sourcing strategies as increased duties on active pharmaceutical ingredients and finished product imports elevate landed costs and pressure established pricing contracts. While some firms have long maintained diversified manufacturing footprints, the tariffs have accelerated discussions around nearshoring, dual-sourcing, and strategic inventory positioning to preserve continuity of care and minimize disruption to critical therapeutic cohorts.

Clinical trial operations have also felt the ripple effects as sponsors re-evaluate site selection, import/export logistics for investigational products, and the cost calculus associated with multinational protocol execution. Regulatory authorities and ethical review boards have engaged with sponsors to ensure participant access is not compromised in cross-border studies, particularly where specialized biologic formulations require controlled temperature logistics and robust distribution partners. Health systems and payers are scrutinizing the downstream impact on formulary decisions and procurement cycles, weighing the cost pressure against clinical necessity and negotiated rebates or patient access programs.

In response, commercial teams are recalibrating contracting strategies with payers and distributors, emphasizing transparent cost drivers and supply continuity assurances. Manufacturers with integrated supply chain capabilities are better positioned to mitigate near-term volatility, while others are exploring collaborative frameworks with logistics partners to stabilize delivery timelines. Ultimately, tariff-induced pressures are catalyzing a strategic reorientation toward supply resilience, pricing transparency, and adaptive commercialization tactics that preserve patient access amid shifting trade environments.

Granular segmentation across product classes, treatment lines, channels, administration routes, and end users reveals actionable differentiation in clinical and commercial strategies

Deep segmentation analysis reveals differentiated dynamics across product classes, treatment lines, distribution channels, routes of administration, and end-user settings that materially influence clinical and commercial choices. Within product classes, conventional disease-modifying antirheumatic drugs encompass agents such as hydroxychloroquine, methotrexate, and sulfasalazine that remain foundational for certain patient profiles, particularly when clinicians aim to manage comorbid features or limit exposure to biologics. IL-17 inhibitors, represented by brodalumab, ixekizumab, and secukinumab, have carved a distinct niche where axial inflammation biomarkers and clinical phenotype suggest higher likelihood of response. Janus kinase inhibitors including filgotinib, tofacitinib, and upadacitinib provide an oral targeted option that appeals to patients seeking convenience and rapid onset of symptomatic control.

Nonsteroidal anti-inflammatory drugs such as diclofenac, ibuprofen, and naproxen continue to play a central role for symptomatic relief and flare management, while the broad class of tumor necrosis factor inhibitors, including adalimumab, certolizumab, etanercept, golimumab, and infliximab, remains a proven cornerstone for many moderate-to-severe cases. Treatment line segmentation further shapes clinical pathways: first-line approaches emphasize rapid inflammation control and functional preservation, second-line decisions reflect response durability and safety trade-offs, and third-line strategies integrate prior biologic exposure, comorbidity profiles, and tolerance history.

Distribution channel and route of administration considerations also inform adoption patterns. Hospital pharmacies and specialty clinics often manage infusion-based regimens and initial biologic initiations, whereas retail and online pharmacies facilitate maintenance dispensing, home administration, and adherence support for oral and injectable therapies. Injectable, intravenous, and oral routes each carry implications for patient convenience, monitoring requirements, and cost structures. End-user segmentation across home care, hospitals, and specialty clinics determines where education, infusion capacity, and long-term monitoring resources must be concentrated to ensure optimal outcomes. Taken together, these intersecting segmentation layers reveal clear opportunities for targeted clinical protocols, differentiated commercial approaches, and channel-specific patient support models.

Regional variations in regulation, payer models, and healthcare infrastructure create differentiated pathways to access that require customized evidence and distribution strategies

Regional dynamics reflect divergent epidemiology, regulatory environments, payer frameworks, and healthcare delivery infrastructures that shape access and strategy. In the Americas, health systems exhibit a mix of private and public payer mechanisms with an emphasis on outcomes-based contracting and specialty pharmacy networks that can facilitate access to advanced biologics and oral targeted agents. Real-world data initiatives and patient registries in this region are increasingly leveraged to support value narratives and reimbursement discussions, while telehealth expansion has strengthened remote monitoring and adherence interventions.

The Europe, Middle East & Africa region presents varied regulatory landscapes and procurement practices. In parts of Europe, centralized reimbursement deliberations and health technology assessment processes place significant weight on comparative effectiveness, quality-of-life outcomes, and long-term safety data. In the Middle East and Africa, variable infrastructure and funding models create pockets of both advanced specialty care delivery and constrained access, making partnerships with regional distributors and investment in local capacity building strategic priorities for manufacturers and service providers.

Asia-Pacific is characterized by rapid adoption of innovative therapies in certain markets, alongside distinct regulatory pathways and local manufacturing expectations in others. National strategies emphasizing domestic pharmaceutical capabilities and evolving reimbursement policies influence how novel agents are introduced and scaled. Cross-border supply chain considerations and differing clinical guideline adoption timelines further contribute to a mosaic of access and uptake patterns. Across all regions, stakeholders benefit from tailoring clinical evidence generation, market access strategies, and distribution partnerships to the specific regulatory, payer, and infrastructure realities they face.

Competitive advantage will depend on differentiated evidence, integrated patient support, supply reliability, and strategic partnerships across the therapy lifecycle

Competitive dynamics in axial spondyloarthritis are shaped by established biologic franchises, emergent targeted small molecules, and specialized service providers that support infusion, distribution, and patient support. Incumbent tumor necrosis factor inhibitor portfolios continue to leverage long-standing clinical experience and extensive safety datasets, while newer classes, including interleukin-17 inhibitors and Janus kinase inhibitors, concentrate on demonstrating clinical differentiation in specific patient cohorts and offering alternative routes of administration or dosing convenience.

Strategic imperatives for leading companies include deep investment in head-to-head and real-world comparative studies, development of robust patient support ecosystems to facilitate adherence for home-administered therapies, and expansion of manufacturing or distribution capabilities to ensure supply continuity. Partnerships between pharmaceutical sponsors and specialty pharmacy networks or infusion service providers are increasingly common as a means to streamline initiation, monitoring, and reimbursement workflows. Additionally, companies are prioritizing lifecycle management through formulation improvements, indication expansion studies, and evidence generation that supports positioning across treatment lines.

New entrants and smaller biopharma players are differentiating through niche clinical programs, biomarker-driven trials, and collaborations with diagnostic developers to enable more targeted prescribing. For commercial leaders, the ability to align clinical value messaging with payer expectations, demonstrate operational excellence in supply and distribution, and deploy digital-first patient engagement tools will determine competitive positioning and long-term success in the axial spondyloarthritis landscape.

Prioritize integrated evidence generation, supply resilience, payer collaboration, tailored commercialization, and education to convert clinical innovation into sustainable patient impact

Industry leaders should prioritize a set of pragmatic, high-impact actions to navigate clinical complexity, policy shifts, and commercial pressures. First, align evidence generation with both regulatory and payer expectations by investing in comparative effectiveness research, real-world data capture, and patient-reported outcome studies that clarify long-term benefits and safety profiles. Second, strengthen supply chain resilience through diversification of manufacturing footprints, strategic inventory management, and collaborative logistics partnerships that mitigate trade-policy and tariff-related disruptions.

Third, design tailored commercialization strategies that consider the interplay between product class, treatment line, distribution channel, and route of administration; for example, pairing oral targeted therapies with digital adherence programs and leveraging specialty pharmacy networks for complex biologic initiations. Fourth, engage proactively with payers and health technology assessment bodies to co-develop value propositions that emphasize functional outcomes, reduction in flares, and long-term disability avoidance rather than episodic symptom relief. Finally, invest in clinician and patient education to shorten diagnostic delays and support shared decision-making, thereby improving initiation timing and persistence with high-value therapies.

Taken together, these actions form an integrated roadmap that balances clinical innovation with operational readiness and market access acumen, enabling organizations to sustain growth while improving patient outcomes in axial spondyloarthritis.

A multidisciplinary, evidence-weighted methodology combining peer-reviewed science, expert interviews, regulatory analysis, and operational intelligence to produce actionable clinical and commercial insights

This research synthesis draws on a multidisciplinary methodology that integrates primary and secondary sources, expert consultations, and structured evidence appraisal to deliver a comprehensive perspective on axial spondyloarthritis. Clinical and scientific literature, guideline documents, regulatory communications, and peer-reviewed studies provided the foundation for disease biology, therapeutic mechanisms, and safety profiles. These insights were augmented by targeted interviews with clinicians, specialty pharmacists, and market access leads to capture real-world practice patterns, diagnostic workflows, and payer negotiation dynamics.

Supply chain and policy analyses incorporated trade publications, manufacturer disclosures, and logistics partner briefings to assess the operational impacts of tariff changes and distribution constraints. Competitive landscape mapping involved a synthesis of public company disclosures, clinical trial registries, and product labeling to evaluate positioning, development strategies, and lifecycle management approaches. Evidence quality was graded using transparent criteria that emphasized study design, population relevance, and applicability to contemporary clinical practice.

Where possible, synthesis favored longitudinal and comparative data to illuminate differential effectiveness and safety patterns. The methodological approach balanced depth with pragmatic relevance, aiming to produce findings that are both evidence-based and actionable for clinical leaders, commercial strategists, and policy stakeholders.

Synthesize clinical advances, operational resilience, and strategic partnerships into a cohesive approach that accelerates patient-centered outcomes and sustainable access

Axial spondyloarthritis presents both persistent challenges and clear areas of opportunity for clinical innovation and strategic action. Diagnostic delays and heterogenous patient responses continue to complicate care pathways, yet the expanding therapeutic arsenal-including biologics and targeted small molecules-offers new avenues to achieve durable disease control and improve long-term function. Policy developments and trade dynamics introduce operational complexity, but they also motivate beneficial investments in supply resilience, manufacturing diversification, and transparent contracting.

Strategically, successful stakeholders will align robust evidence generation with pragmatic commercialization and access tactics that reflect segment-specific drivers, regional regulatory realities, and evolving payer expectations. Partnerships across the ecosystem-from diagnostics and specialty pharmacies to distribution and digital health providers-can accelerate adoption and optimize patient journeys. Ultimately, the path forward requires coordinated efforts that combine clinical rigor, operational excellence, and a patient-centered focus to translate therapeutic advances into measurable improvements in quality of life for people living with axial spondyloarthritis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of JAK inhibitors for nonradiographic axial spondyloarthritis patients unresponsive to first-line TNF blockers
  • 5.2. Increasing investment in biomarker-driven diagnostics enabling early detection of axial spondyloarthritis progression
  • 5.3. Expansion of telemedicine platforms integrating patient-reported outcomes for remote monitoring of disease activity
  • 5.4. Emergence of bispecific antibody candidates targeting both TNF and IL-17 pathways in pipeline trials
  • 5.5. Growing competition from biosimilar etanercept and adalimumab affecting pricing and market access strategies
  • 5.6. Implementation of quantitative MRI scoring algorithms to improve early diagnosis and treatment stratification
  • 5.7. Adoption of value-based contracting models with payers emphasizing long-term functional outcomes in axial spondyloarthritis biologics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Axial Spondyloarthritis Market, by Product Class

  • 8.1. Conventional DMARDs
    • 8.1.1. Hydroxychloroquine
    • 8.1.2. Methotrexate
    • 8.1.3. Sulfasalazine
  • 8.2. IL-17 Inhibitors
    • 8.2.1. Brodalumab
    • 8.2.2. Ixekizumab
    • 8.2.3. Secukinumab
  • 8.3. JAK Inhibitors
    • 8.3.1. Filgotinib
    • 8.3.2. Tofacitinib
    • 8.3.3. Upadacitinib
  • 8.4. NSAIDs
    • 8.4.1. Diclofenac
    • 8.4.2. Ibuprofen
    • 8.4.3. Naproxen
  • 8.5. TNF Inhibitors
    • 8.5.1. Adalimumab
    • 8.5.2. Certolizumab
    • 8.5.3. Etanercept
    • 8.5.4. Golimumab
    • 8.5.5. Infliximab

9. Axial Spondyloarthritis Market, by Treatment Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Axial Spondyloarthritis Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Axial Spondyloarthritis Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Intravenous
  • 11.3. Oral

12. Axial Spondyloarthritis Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Axial Spondyloarthritis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Axial Spondyloarthritis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Axial Spondyloarthritis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Novartis AG
    • 16.3.3. Janssen Biotech, Inc.
    • 16.3.4. Eli Lilly and Company
    • 16.3.5. UCB S.A.
    • 16.3.6. Amgen Inc.
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRI